{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:27:01Z","timestamp":1791192421669,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives de P\u00e9diatrie"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.arcped.2016.06.002","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T14:37:43Z","timestamp":1469025463000},"page":"966-973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Posologie des antibiotiques chez le nouveau-n\u00e9\u00a0: variations des pratiques et comment y rem\u00e9dier\u00a0?"],"prefix":"10.1016","volume":"23","author":[{"given":"S.","family":"Leroux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Biran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4285-7067","authenticated-orcid":false,"given":"E.","family":"Jacqz-Aigrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.arcped.2016.06.002_bib0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/INF.0b013e31819587a9","article-title":"Neonatal sepsis: a major global public health challenge","volume":"28","author":"Qazi","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl. 3","key":"10.1016\/j.arcped.2016.06.002_bib0260","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/14767058.2010.501156","article-title":"Long-term effects of neonatal drugs on the kidney","volume":"23","author":"Zaffanello","year":"2010","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.arcped.2016.06.002_bib0265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/jp.2012.105","article-title":"Ototoxicity in preterm infants: effects of genetics, aminoglycosides, and loud environmental noise","volume":"33","author":"Zimmerman","year":"2013","journal-title":"J Perinatol"},{"key":"10.1016\/j.arcped.2016.06.002_bib0270","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jpeds.2014.09.041","article-title":"Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics","volume":"166","author":"Arboleya","year":"2015","journal-title":"J Pediatr"},{"issue":"Suppl. 2","key":"10.1016\/j.arcped.2016.06.002_bib0275","first-page":"105","article-title":"Clinical implications of antimicrobial resistance for therapy","volume":"62","author":"Macgowan","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.arcped.2016.06.002_bib0280","doi-asserted-by":"crossref","first-page":"F438","DOI":"10.1136\/archdischild-2013-305900","article-title":"Neonatal drug trials: impact of EU and US paediatric regulations","volume":"99","author":"Pansieri","year":"2014","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"10.1016\/j.arcped.2016.06.002_bib0285","series-title":"R\u00e8glement (CE) No 1901\/2006\u00a0du parlement europ\u00e9en et du conseil, relatif aux m\u00e9dicaments \u00e0 usage p\u00e9diatrique","author":"Le parlement europ\u00e9en et le conseil de l\u2019union europ\u00e9enne","year":"2006"},{"key":"10.1016\/j.arcped.2016.06.002_bib0290","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/pds.1858","article-title":"Compliance with dosing recommendations from common references in prescribing antibiotics for preterm neonates","volume":"19","author":"Cheng","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.arcped.2016.06.002_bib0295","series-title":"Pediatric dose handbook: including neonatal dosing, drug administration, & extemporaneous preparations","author":"Taketomo","year":"2002"},{"key":"10.1016\/j.arcped.2016.06.002_bib0300","series-title":"Neofax","author":"Young","year":"2002"},{"key":"10.1016\/j.arcped.2016.06.002_bib0305","series-title":"Neonatal drug formulary","author":"Batt","year":"2002"},{"key":"10.1016\/j.arcped.2016.06.002_bib0310","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1093\/jac\/dkr351","article-title":"Variation in gentamicin and vancomycin dosage and monitoring in UK neonatal units","volume":"66","author":"Kadambari","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.arcped.2016.06.002_bib0315","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/archdischild-2014-306873","article-title":"Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: a French national survey","volume":"100","author":"Leroux","year":"2015","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.arcped.2016.06.002_bib0320","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.siny.2004.11.003","article-title":"The use of unlicensed and off-label medicines in the neonate","volume":"10","author":"Conroy","year":"2005","journal-title":"Semin Fetal Neonatal Med"},{"key":"10.1016\/j.arcped.2016.06.002_bib0325","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/clpt.2012.26","article-title":"Off-label drug use in pediatric patients","volume":"91","author":"Kimland","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.arcped.2016.06.002_bib0330","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-3-642-20195-0_2","article-title":"Developmental pharmacokinetics","volume":"205","author":"Van den Anker","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.arcped.2016.06.002_bib0335","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00467-005-2105-4","article-title":"Ontogeny of drug elimination by the human kidney","volume":"21","author":"Chen","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.arcped.2016.06.002_bib0340","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology \u2013\u00a0drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcped.2016.06.002_bib0345","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1472-8206.2003.00140.x","article-title":"Drug metabolism and disposition in children","volume":"17","author":"Strolin Benedetti","year":"2003","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.arcped.2016.06.002_bib0350","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00467-008-0997-5","article-title":"Human renal function maturation: a quantitative description using weight and postmenstrual age","volume":"24","author":"Rhodin","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.arcped.2016.06.002_bib0355","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1128\/AAC.03568-14","article-title":"Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age","volume":"58","author":"Zhao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcped.2016.06.002_bib0360","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/11595640-000000000-00000","article-title":"Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance","volume":"51","author":"De Cock","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.arcped.2016.06.002_bib0365","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bcp.12602","article-title":"Cystatin C as a potential biomarker for dosing of renally excreted drugs","volume":"80","author":"Brou","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.arcped.2016.06.002_bib0370","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/archdischild-2012-302765","article-title":"Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring","volume":"98","author":"Zhao","year":"2013","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.arcped.2016.06.002_bib0375","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drup.2011.02.005","article-title":"Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective","volume":"14","author":"Mouton","year":"2011","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.arcped.2016.06.002_bib0380","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.siny.2004.10.004","article-title":"New dosing strategies for antibacterial agents in the neonate","volume":"10","author":"De Hoog","year":"2005","journal-title":"Semin Fetal Neonatal Med"},{"key":"10.1016\/j.arcped.2016.06.002_bib0385","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.arcped.2016.06.002_bib0390","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/QCO.0b013e328337bb42","article-title":"Understanding pharmacokinetics\/pharmacodynamics in managing neonatal sepsis","volume":"23","author":"Lutsar","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.arcped.2016.06.002_bib0395","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1574-6976.2011.00295.x","article-title":"Emergence and spread of antibiotic resistance following exposure to antibiotics","volume":"35","author":"Cant\u00f3n","year":"2011","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.arcped.2016.06.002_bib0400","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.addr.2014.01.002","article-title":"Pharmacokinetic\/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology","volume":"73","author":"Barker","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.arcped.2016.06.002_bib0405","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1254\/jphs.13126FP","article-title":"Pharmacokinetic variability of amikacin after once-daily and twice-daily dosing regimen in full-term neonates","volume":"124","author":"Vu\u010di\u0107evi\u0107","year":"2014","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.arcped.2016.06.002_bib0410","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/FTD.0000000000000071","article-title":"Impact of clinical decision support guidelines on therapeutic drug monitoring of gentamicin in newborns","volume":"36","author":"Fonzo-Christe","year":"2014","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.arcped.2016.06.002_bib0415","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000014053","article-title":"Adaptation in neonatology of the once daily concept of aminoglycoside administration: evaluation of a dosing chart for amikacin in an intensive care unit","volume":"74","author":"Langhendries","year":"1998","journal-title":"Biol Neonate"},{"key":"10.1016\/j.arcped.2016.06.002_bib0420","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1542\/peds.103.3.594","article-title":"Once- versus twice-daily gentamicin dosing in neonates >\/=34\u00a0weeks\u2019 gestation: cost-effectiveness analyses","volume":"103","author":"Thureen","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.arcped.2016.06.002_bib0425","series-title":"Pediatric and neonatal dosage handbook","author":"Taketomo","year":"2014-2015"},{"key":"10.1016\/j.arcped.2016.06.002_bib0430","series-title":"Manual of childhood infections. The blue book","author":"Sharland","year":"2011"},{"key":"10.1016\/j.arcped.2016.06.002_bib0435","series-title":"Neofax","author":"Young","year":"2011"},{"key":"10.1016\/j.arcped.2016.06.002_bib0440","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00228-012-1413-4","article-title":"Population pharmacokinetics of piperacillin\/tazobactam in neonates and young infants","volume":"69","author":"Li","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.arcped.2016.06.002_bib0445","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/bcp.12113","article-title":"Randomized controlled trials of antibiotics for neonatal infections: a systematic review","volume":"76","author":"Kaguelidou","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.arcped.2016.06.002_bib0450","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.pcl.2012.07.004","article-title":"How to optimize the evaluation and use of antibiotics in neonates","volume":"59","author":"Jacqz-Aigrain","year":"2012","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.arcped.2016.06.002_bib0455","series-title":"Ethical considerations for clinical trials on medicinal products conducted with the paediatric population","author":"European Medicines Agency","year":"2008"},{"key":"10.1016\/j.arcped.2016.06.002_bib0460","series-title":"Guideline on the investigation of medicinal products in the term and preterm neonat","author":"European Medicines Agency","year":"2010"},{"key":"10.1016\/j.arcped.2016.06.002_bib0465","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40262-015-0291-1","article-title":"Pharmacokinetic studies in neonates: the utility of an opportunistic sampling design","volume":"54","author":"Leroux","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.arcped.2016.06.002_bib0470","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/FTD.0b013e3182587665","article-title":"Population pharmacokinetics of piperacillin using scavenged samples from preterm infants","volume":"34","author":"Cohen-Wolkowiez","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.arcped.2016.06.002_bib0475","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1128\/AAC.02139-13","article-title":"Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants","volume":"58","author":"Cohen-Wolkowiez","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcped.2016.06.002_bib0480","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/bmc.1523","article-title":"Determination of ciprofloxacin in plasma by micro-liquid chromatography-mass spectrometry: an adapted method for neonates","volume":"25","author":"Grondin","year":"2011","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.arcped.2016.06.002_bib0485","series-title":"Guidance for industry exposure-response relationships \u2014\u00a0study design, data analysis, and regulatory applications","author":"Food and Drug Administration","year":"2003"},{"key":"10.1016\/j.arcped.2016.06.002_bib0490","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.prrv.2007.04.004","article-title":"The European Regulation on medicines for paediatric use","volume":"8","author":"Dunne","year":"2007","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.arcped.2016.06.002_bib0495","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1753-2000-2-37","article-title":"Regulation (EC) No 1901\/2006\u00a0on medicinal products for paediatric use & clinical research in vulnerable populations","volume":"2","author":"Lehmann","year":"2008","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"10.1016\/j.arcped.2016.06.002_bib0500","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1542\/peds.2004-1915","article-title":"Age terminology during the perinatal period","volume":"114","author":"Engle","year":"2004","journal-title":"Pediatrics"}],"container-title":["Archives de P\u00e9diatrie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929693X16302767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929693X16302767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T06:53:08Z","timestamp":1536562388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929693X16302767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0929693X16302767"],"URL":"https:\/\/doi.org\/10.1016\/j.arcped.2016.06.002","relation":{},"ISSN":["0929-693X"],"issn-type":[{"value":"0929-693X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Posologie des antibiotiques chez le nouveau-n\u00e9\u00a0: variations des pratiques et comment y rem\u00e9dier\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Archives de P\u00e9diatrie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcped.2016.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}